Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat

Lancet Oncol. 2016 Dec;17(12):1622-1623. doi: 10.1016/S1470-2045(16)30506-X. Epub 2016 Oct 14.
No abstract available

Publication types

  • Comment

MeSH terms

  • Acrylamides
  • Aniline Compounds
  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Lung Neoplasms
  • Piperazines*

Substances

  • Acrylamides
  • Aniline Compounds
  • Piperazines
  • osimertinib